Amarin (United Kingdom)

Amarin (United Kingdom)

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Amarin (United Kingdom), United Kingdom, covering academic research published from 2005 to 2024. Read More.


Open Access Percentage

78%


Total
Publications

178


Total Open
Publications

138


Total
Citations

1.8K


Open Access
Percentage

78%


Total
Publications

178


Total Open
Publications

138


Total
Citations

1.8K

Wikipedia

Website

download

Breakdown

64% 13% 1% 22%

Publisher Open

64%

Both

13%

Other Platform Open

1%

Closed

22%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
20052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

02468101214161820222426Total Publications
20052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

7%OA Journal

OA Journal 7%

9

Hybrid 80%

109

No Guarantees 13%

18

Other Platform Open

Domain 84%

21

Institution 40%

10

Public 8%

2

Preprint 4%

1

Other Internet 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
19
Europe PMC
Domain
12
Erasmus University Rotterdam - EUR Research Repository
Institution
3
University of Oxford - Oxford University Research Archive (ORA)
Institution
2
University of Dundee - Discovery Research Portal
Institution
2
Semantic Scholar
Public
2
Le Centre pour la Communication Scientifique Directe - HAL - Inria
Institution
2
BRAC University - BRAC University Institutional Repository
Institution
2
whiterose.ac.uk OAI-PMH Repository
Institution
1
Università degli Studi di Brescia - Institutional Research Information System
Institution
1
1 / 2

Data updated 7 April 2025

Share

Share

Share